Search

Language:中文ENGLISH

E-mail: sales_liu@bonabio.cn

Whatsapp: +86-18963064736

Wechat: +86-18963064736

QQ: 2862752579

TM: Bonabio

Address: Block D, Century Fortune Center, High-tech Zone, Jinan City, Shandong Province, China

Copyright(c)2020  ©  Shandong Bona Biological Technology Group Co., Ltd. 鲁ICP备12034225号-5

CONTACT US

PRODUCTS

ABOUT US

MESSAGES

NEWS

NEWS

BONA BIOTECHNOLOGY GROUP

Drug development for urea cycle disorders

Classification:
Industry News
Author:
Source:
Release time:
2020/10/27 10:41
Page view
[Abstract]:

Urea cycle disorder is an inherited metabolic disorder. The human body excretes the protein metabolite ammonia from the body through the urea cycle, and when this cycle is blocked, ammonia will accumulate in the blood. When the concentration of ammonia in the blood is high enough, it will cause brain damage, coma or death. The incidence of neonatal urea cycle disorders is 1 in 10,000.
      Not long ago, the final clinical trial of HPN-100, an innovative drug used by Hyperion Therapeutics for urea cycle disorders in the United States, obtained positive results. This research result provided a guarantee that the drug was approved by the FDA in September 2011. Christine Nash, vice president of Hyperion Therapeutics, estimates that the drug has a market prospect of $200 million. In addition, Medicis Pharmaceuticals has an FDA-approved adjuvant drug Ammonul for acute hyperammonemia and related encephalopathy in patients with urea cycle-related enzyme defects.